Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan
Journal
Cancers
Journal Volume
15
Journal Issue
17
Date Issued
2023-08-26
Author(s)
Abstract
Thiazolidinedione (TZD) exerts anti-proliferative effects on multiple myeloma (MM) cells. However, there has not been any human study investigating the risk of MM associated with TZD use.
Subjects
multiple myeloma; pharmacoepidemiological study; pioglitazone; rosiglitazone; thiazolidinedione
SDGs
Type
journal article